The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group
Kessler, C.M.; Ludlam, C.A.
Seminars in Hematology 30(2 Suppl. 1): 22-27
1993
ISSN/ISBN: 0037-1963 PMID: 8480193 Document Number: 407645
Document emailed within 1 workday
Related Documents
Brettler, D.B.; Forsberg, A.D.; Levine, P.H.; Aledort, L.M.; Hilgartner, M.W.; Kasper, C.K.; Lusher, J.M.; McMillan, C.; Roberts, H. 1989: The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience Archives of Internal Medicine 149(6): 1381-1385Lottenberg, R.; Kentro, T.B.; Kitchens, C.S. 1987: Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy Archives of Internal Medicine 147(6): 1077-1081
Takahashi, I.; Furuta, M.; Mizuno, S.; Takamatsu, J.; Kamiya, T. 1993: Effect of substrate and diluent for factor VIIi activity in highly purified factor VIIi concentrate and patient plasma infused factor VIIi concentrate Rinsho Byori. Japanese Journal of Clinical Pathology 41(7): 825-830
Teitel, J.M.; Lau, H.K.; Garvey, M.B. 2002: Discrepancies in measured factor VIIi activity in patients treated with factor VIIi concentrate of human or porcine origin Thrombosis and Haemostasis 88(1): 159-160
Petrovic, M.; Derom, E.; Baele, G. 2000: Cyclosporine treatment of acquired hemophilia due to factor VIIi antibodies Haematologica 85(8): 895-896
Ewing, N.P. 1990: Induction of immune tolerance with factor VIIi concentrate in patients with hemophilia a and inhibitors Progress in Clinical and Biological Research 324: 59-68
Walker, I.; Poon, M.C. 1992: Recombinant factor VIII concentrate. The MSAC, Canadian Hemophilia Society. Canadian Hemophilia Clinic Directors Group Lancet 339(8784): 61-62
Green, D. 1994: Immunosuppression of patients with acquired factor VIIi inhibitors Seminars in Hematology 31(2 Suppl 4: 60-61
Kunst, V.A.; Nováková, I.R.; Haanen, C. 1989: Cryoprecipitate should have preference over factor VIII concentrate in the treatment of patients with hemophilia A Nederlands Tijdschrift Voor Geneeskunde 133(23): 1163-1166
Allersma, D.P.; Smid, W.M.; van der Does, J.A.; van der Meer, J.; Briët, E. 1996: Effects of chronic factor VIII substitution on immune parameters in HIV seronegative haemophiliacs: a comparison between cryoprecipitate and factor VIII concentrate Thrombosis and Haemostasis 75(2): 261-266
Mahasandana, C.; Suvatte, V.; Püng-amritt, P.; Tuchinda, S. 1979: Von Willebrand's disease: studies of platelet functions, factor VIII procoagulant activity (F VIII C) and factor VIII-related antigen (F VIII RAg) in three families Southeast Asian Journal of Tropical Medicine and Public Health 10(2): 243-247
Ambriz-Fernández, R.; Reyna-Fregoso, M.P.; Pizzuto-Chávez, J.; Rodríguez-Moyado, H.; Farfán-Canto, J.M.; Trueba-Christy, E.; Collazo-Jaloma, J. 1985: Kinetics of the inhibitor of factor VIII:C in patients with hemophilia A. a study of the cooperative group of hemophilia Archivos de Investigacion Medica 16(3): 225-235
Brown, J.E.; Carton, C.L.; Hougie, C. 1981: The effect of naturally occurring antibodies to factor VIIi on an immunoradiometric assay for factor VIIi coagulant antigen. Observation on a cross-reacting material-positive (CRM+) hemophiliac with a factor VIIi inhibit Journal of Laboratory and Clinical Medicine 97(1): 65-71
Gatti, L.; Mannucci, P.M. 1984: Use of porcine factor VIII in the management of seventeen patients with factor VIII antibodies Thrombosis and Haemostasis 51(3): 379-384
Mahasandana, C.; Patharathienskul, D.; Suvatte, V. 1993: Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management Southeast Asian Journal of Tropical Medicine and Public Health 24(Suppl 1): 106-112
Hay, C.R.; Lozier, J.N.; Lee, C.A.; Laffan, M.; Tradati, F.; Santagostino, E.; Ciavarella, N.; Schiavoni, M.; Fukui, H.; Yoshioka, A.; Teitel, J.; Mannucci, P.M.; Kasper, C.K. 1996: Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: the results of an international survey Thrombosis and Haemostasis 75(1): 25-29
Muntean, W. 1984: Purified complex of factor VIII coagulant moiety and phospholipid: high factor VIII coagulant activity in factor VIII inhibitor plasma Wiener Klinische Wochenschrift 96(22): 829-832
Mannucci, P.M.; Zanetti, A.R.; Colombo, M.; Chistolini, A.; De Biasi, R.; Musso, R.; Tamponi, G. 1990: Antibody to hepatitis C virus after a vapour-heated factor VIIi concentrate. the Study Group of the Fondazione dell'Emofilia Thrombosis and Haemostasis 64(2): 232-234
Fijnvandraat, K.; Berntorp, E.; ten Cate, J.W.; Johnsson, H.; Peters, M.; Savidge, G.; Tengborn, L.; Spira, J.; Stahl, C. 1997: Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients Thrombosis and Haemostasis 77(2): 298-302
Tran, T.H.; Duckert, F. 1983: Dissociation of factor VIIi procoagulant antigen VIII:CAg and factor VIIi related antigen VIIIR:Ag by EDTA - influence of divalent cation on the binding of VIII:CAg and VIIIR:Ag Thrombosis and Haemostasis 50(2): 547-551